Proactive Investors USA & CanadaCell Therapeutics Announces European Launch Of Pixuvri® For Treatment Of …The Herald | HeraldOnline.comThe European Medicines Agency's (the "EMA") Committee for Medicinal Products for Human Use has accep…

'No malignancy risk' with biologic response modifiersNews-Medical.net… Cancer Center in Houston, Texas, USA, and colleagues identified 63 studies reporting safety data for a total of 29,423 RA patients treated with abatacept, adalimumab, anak…

Doctor suspended, fined for inappropriate treatmentTODAYonlineDr Teoh had recommended and administered a therapy – Rituximab, Velcade, Dexamethasone, Thalidomide, Zometa therapy, also known as the VELCADE-based Therapy – that he should have known, or k…

Pharmacyclics Management Discusses Q4 2012 Results – Earnings Call TranscriptSeeking AlphaThis is Phase III study of ibrutinib in combination with bendamustine/rituximab in patients with relapsed or refractory CLL or SLL. This is a randomized, multicen…

Pharmacyclics Reports Fourth Quarter and Full Year Fiscal 2012 Financial …Sacramento BeePhase III study of ibrutinib in combination with bendamustine and rituximab in patients with relapsed/refractory CLL/SLL: A randomized, multi-center Phase III, do…

TG Therapeutics, Inc. Initiates a Phase I/II Clinical Trial of Its Novel Third …NASDAQ… the company's novel third-generation anti-CD20 monoclonal antibody, for patients with relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL) who wer…

Pharmacyclics Reports Fourth Quarter And Full Year Fiscal 2012 Financial …Daily MarketsPhase III study of ibrutinib in combination with bendamustine and rituximab in patients with relapsed/refractory CLL/SLL: A randomized, multi-center Phase III, dou…

Pharmacyclics Reports Fourth Quarter and Full Year Fiscal 2012 Financial …The Herald | HeraldOnline.comPhase III study of ibrutinib in combination with bendamustine and rituximab in patients with relapsed/refractory CLL/SLL: A randomized, multi-cente…

BiolineRX licenses Clal Biotech unit leukemia drugGlobesPre-clinical studies show that BL-8040 is efficient, both alone and in combination with the anti-cancer drug Rituximab, in reducing bone marrow metastasis of lymphoma cells and stimulating lymphom…

Dr Reddy's plans EU launch for biosimilar cancer treatmentZenopaDr Reddy's Laboratories is planning to launch a biosimilar version of Roche's non-Hodgkin's lymphoma treatment rituximab in Europe. The company is in talks with European re…